Drugs / Recombinant GM-CSF
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT00083551 Comparator | Aug 1998 → Aug 2014 | plasma cell myeloma | University of Arkansas | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant GM-CSF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00083551 ↗ |
| Route | Subcutaneous | “GM-CSF at a dose of 10 μg/kg SC” NCT00083551 ↗ |